Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals aged between 19 and 80 years old.~2. The following patients who belong to the low-risk group to the very-high risk group according to 2015 Korean guidelines for the management of dyslipidemia (Committee, KCJ 2016).~   * Very high risk group (coronary artery disease, ischemic stroke, peripheral vascular disease) were not receiving lipid-lowering agents (statins) within 4 weeks of the screening, regardless of LDL-C levels~  * High risk group (carotid artery disease, abnormal aneurysm, diabetes)\* : LDL-C ≥ 100 mg/dl~  * Moderate risk group (2 or more major risk factors)\* : LDL-C ≥ 130 mg/dl~  * Low risk group (less than 1 major risk factors)\* : LDL-C ≥ 160 mg/dl~     * If the patients taka a lipid-lowering agents (statin) within 4 weeks of screening, enrolled them after wash-out for 4 weeks or more.~3. Patients who voluntarily participated in the trial and obtained document consent.~Exclusion Criteria:~1. a history of acute arterial disease (patients with unstable angina myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within 3 months prior to study enrollment)~2. uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥100mmHg)~3. uncontrolled diabetes (hemoglobin A1c ≥9% or fasting glucose ≥160mg/dl)~4. uncontrolled thyroid dysfunction (thyroid stimulation hormone ≥1.5 times the upper limits of normal (ULN))~5. usage of antihyperlipidemic drugs (bile acid sequestrants, fibrates, niacin, etc.) within 4 weeks before enrollment~6. a history of myopathy, rhabdomyolysis or elevated serum creatinine kinase (CK) more than 2 times the ULN~7. chronic kidney disease (serum creatinine ≥2 times the ULN)~8. elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 times the ULN)~9. a history of drug or alcohol abuse~10. a history of gastrointestinal surgery or gastrointestinal tract disorders~11. hypersensitivity to the components of this drug~12. those who disagree with contraception~13. pregnancy and/or lactation.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 10mg of the generic formulation (rosuvastatin, ROVASRO®) (Type: ACTIVE_COMPARATOR): Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
- 10mg of the reference formulation (rosuvastatin, CRESTOR®) (Type: ACTIVE_COMPARATOR): Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)

Based on this trial design, predict the completion outcome and termination type (if applicable).